Mannitol Approved as Add-On Maintenance Therapy for Cystic Fibrosis
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Ivacaftor was safe and associated with improvements in cystic fibrosis transmembrane conductance regulator function in infants with CF and a gating mutation.
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
Intravenous antibiotics do not achieve greater sustained eradication of Pseudomonas aeruginosa in patients with cystic fibrosis compared with oral therapy.
The approval was based on data from a phase 3 open-label safety study that included a cohort of 6 children 4 months to <6 months of age.
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Age may influence outcomes in lung transplant recipients with cystic fibrosis.
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
In patients with cystic fibrosis, prolonged exposure to heat can lead to chloride-deficient metabolic alkalosis as a result of a loss of electrolytes through sweat.
The FDA has granted Breakthrough Therapy designation to brensocatib for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.